Question 1

What is a complete DBS system, what are the parts, and what does each part do?

Accepted Answer

A complete DBS system is an implanted electrical stimulation system with components that are designed to work together as a single therapy pathway.¹

The core idea is simple but strict: a pulse is generated by electronics in the implanted pulse generator, carried by an extension conductor, and delivered into tissue through contacts on a brain lead.¹  When something changes, symptom return, new side effects, unexpected device alerts, clinicians often localize the problem by thinking in “which segment of the pathway could explain this.”¹ You do not need to be an engineer to follow that reasoning, but you do need the map of parts and their roles.¹

Most DBS systems include three primary implanted components, and many include a few supporting implanted accessories.¹ The components are built to minimize corrosion, fluid ingress, and mechanical stress over years, but they still rely on secure connections and stable electrical properties.¹,² The most common component set includes a brain lead, an extension, and an implantable pulse generator (IPG).¹

The parts of a DBS System have distinct locations, distinct failure modes, and distinct clinic “checkpoints” during follow-up.¹ The goal is not memorization, it is recognizing which part a clinician is referencing when they mention imaging, impedance, header ports, or battery status.¹
 • Brain lead (intracranial electrode): The lead is implanted into a chosen brain target, and it contains multiple metal contacts along its tip.¹ Those contacts define where current can enter or leave tissue, which is why lead placement and contact selection strongly affect benefit and side effects.¹ Some leads are traditional ring designs, and some are segmented directional designs that allow current steering to shape the stimulation field.¹,⁴
 • Extension (lead extension): The extension is an insulated conductor routed under the skin, usually from the head or neck region to the chest region where the IPG sits.¹ Its job is not to “treat” symptoms directly, it is to transmit pulses reliably with minimal signal loss and minimal mechanical strain at junctions.¹ Extension routing and slack management matter because repetitive neck and shoulder motion can transmit forces to connectors over time.¹,²
 • Implantable pulse generator, IPG (aka the battery or generator): The IPG contains the battery and the circuitry that generates pulses, stores programmed settings, and communicates with external programmers and patient controllers.¹ It is also the component that typically reports battery status, can log system diagnostics like impedance, and enforces safety limits on output.¹,²
 • Connector system (often integrated as a header on the IPG): The header provides the physical and electrical connection between extension and IPG, and in some systems it also provides ports to support unilateral or bilateral connections depending on the model.¹,² Because this is a high-consequence junction, manufacturers specify tightening torque, sealing steps, and inspection checks to reduce intermittent contact or fluid-related faults.²

The basic three-component architecture, lead plus extension plus IPG, is consistent across modern DBS systems and is well established in technical reviews and device labeling.¹,² Details of connector designs, lead geometries, and diagnostic reporting vary by manufacturer and by model generation, and the specifics should be confirmed using the exact device labeling for the implanted system.¹,²

Glossary

Deep brain stimulation (DBS): An implanted therapy that delivers programmed electrical pulses to specific brain targets to modify abnormal circuit activity.¹

Brain target: The intended anatomical structure where stimulation is delivered, selected to match symptom goals and risk tradeoffs.³

Brain lead: The implanted electrode placed into the brain target that contains multiple contacts for stimulation delivery.¹

Contact: A metal electrode surface on the lead that can deliver or return current to form a stimulation pattern.¹

Extension: An insulated conductor that connects the brain lead to the IPG under the skin.¹

Implantable pulse generator (IPG): The implanted power source and electronics that generate stimulation pulses and store settings.¹

Header: The connector block on the IPG where the lead extension is secured and electrically connected.²

Directional lead: A lead with segmented contacts that can steer current to shape the stimulation field more precisely.¹,⁴

Question 2

What is the “lead” (brain electrode), and how is it different from the extension and the generator?

Accepted Answer

This question separates the part that touches brain tissue from the parts that carry power and store settings.¹ The distinction matters because lead issues are often evaluated with imaging and clinical maps of contacts, while extension and IPG issues are often evaluated with electrical diagnostics and device interrogation.¹,²

It also matters because replacement decisions, if ever needed, are not symmetric: replacing an IPG is a different procedure and risk profile than revising a brain lead.¹ You will hear clinicians speak precisely when they say “lead location,” “extension integrity,” or “generator status,” and those phrases point to different layers of the system.¹,²

A DBS lead is a long, thin implanted electrode designed to sit in brain tissue with its contact array positioned across a small vertical span of the target region.¹ The extension is a separate insulated conductor that acts as the bridge between the lead and the IPG, and it is usually tunneled under the skin to the generator pocket.¹ The generator, or IPG, is the control and power center, and it determines how pulses are shaped in time, including amplitude, pulse width, and frequency, within programmed safety limits.¹,²

Clinically, lead placement determines what anatomy is reachable, while programming determines how stimulation interacts with the reachable anatomy.¹,³ That separation is why a perfectly functioning device can still have limited benefit if contact locations do not align well with the target, and why a well-placed lead can still cause side effects if programming spreads current into nearby pathways.¹,³

The roles of lead, extension, and IPG are well described in technical reviews and in FDA device labeling.¹,² The relationship between lead location, programming, and outcomes is well supported, but predicting the “best” contact and settings for an individual still relies on clinical testing and remains partly individualized.¹,³

Glossary:

Lead location: The anatomical position of the lead and its contacts relative to the intended brain target, usually assessed with imaging and clinical programming response.¹

Device interrogation: Using a programmer to read device status, diagnostics, and settings from the IPG.²

Amplitude: The strength of stimulation output, expressed as current or voltage depending on system design and programming mode.¹

Pulse width: The duration of each stimulation pulse, which influences which neural elements are recruited at a given amplitude.¹

Frequency: How many pulses per second are delivered, often reported in hertz (Hz).¹

Question 3

What are “contacts” on a DBS lead, and how do they deliver stimulation?

Accepted Answer

This question focuses on the part of DBS that actually interfaces with tissue, the contact array on the lead tip.¹ The same implanted lead can behave like multiple different “stimulation sources” depending on which contacts are active and how they are configured.¹

Your medical team may often talk about “testing contacts,” “selecting an active contact,” or “steering,” and those choices are direct manipulations of which contact surfaces deliver current and where the electric field concentrates.¹,⁴ The practical point is that contacts are the addressable stimulation sites, and they are the reason programming can adjust therapy without moving hardware.¹
A contact is a conductive electrode surface, commonly a ring or a segment of a ring, embedded in the insulating lead body.¹ When a contact is activated as a cathode or anode, current flows through tissue between active and return electrodes, creating an electric field that influences neural elements near the contact.¹ In many DBS systems, multiple contacts can be combined with different polarities, and in some systems current can be distributed across multiple contacts to shape the field more precisely.¹,⁴

A constraint is the electrode-tissue interface, which includes the metal surface, surrounding tissue, and microscopic electrochemical behavior that influences impedance.¹ As impedance changes over time, especially early after implantation, the relationship between programmed output and delivered current distribution can shift, which is one reason clinicians sometimes revisit settings after healing.¹

The principles of contact-based stimulation, electric field shaping, and impedance variability are well supported in technical reviews of DBS system features.¹ Directional lead advantages for current steering are established conceptually and supported by clinical experience, but the size of benefit varies and is not guaranteed for every person or every symptom.¹,⁴

Glossary:

Polarity configuration: The assignment of contacts as active negative (cathode) or positive (anode) to shape current flow.¹

Electric field: The spatial pattern of electrical influence in tissue produced by current flow between electrodes.¹

Impedance: The effective resistance to current flow in the system, influenced by tissue properties, electrode interface, and connection integrity.¹

Electrode-tissue interface: The boundary region where the metal contact meets surrounding tissue, shaping impedance and charge transfer behavior.¹

Current steering: Using segmented contacts and current distribution to shift the stimulation field toward or away from specific anatomy.¹,⁴

Question 4

What is the “connector” (header) area, and why does it matter for reliability and troubleshooting?

Accepted Answer

This question is about a small physical zone that can have outsized consequences for long-term reliability.¹,² The header is where implanted components meet, and it is where mechanical security, sealing, and electrical continuity must all be stable across years of body motion.¹,²

It helps with troubleshooting because many device checks in clinic, including impedance measurements and “open circuit” alerts, can reflect issues at connectors as well as issues in leads or extensions.¹,² Understanding the header helps you interpret what a clinician means when they say “we need to check connections” or “this looks like a lead or extension integrity issue.”¹,²
The header is a connector block attached to the IPG that contains one or more ports where extensions are inserted and secured.²

Manufacturers specify insertion steps and torque requirements because incomplete seating or improper tightening can create intermittent electrical contact, which can appear as fluctuating impedance or inconsistent therapy delivery.² In some device families, the number of header ports relates directly to whether one IPG can support unilateral or bilateral stimulation, because bilateral systems require connections for two leads, usually through two extensions.¹

From a practical standpoint, header integrity can influence how confidently clinicians interpret diagnostics.¹ If impedance is unexpectedly high or shows an “open” pattern, one possibility is a discontinuity in the conductor pathway, which could occur in the lead, extension, or connector region, and the evaluation often combines device interrogation with imaging and history.¹,²

DBS device manuals and regulatory labeling emphasize correct connector handling and describe connection-related precautions, which supports the central role of header integrity in reliability.² Technical reviews also describe how header port count relates to unilateral versus bilateral configurations.¹ The exact failure rates and dominant failure locations vary by system, surgical technique, and patient factors, so specific probabilities should be discussed with the treating center using their experience and the device’s post-market data.¹,²

Glossary

Connector/header: The IPG component that contains ports and fastening mechanisms to secure extensions and complete the electrical pathway.²

Port: A specific socket in the header designed to accept an extension connector.¹,²

Torque requirement: A manufacturer-specified tightening level intended to secure the connector without damaging components.²

Open circuit: A diagnostic pattern suggesting a discontinuity in the electrical pathway, often reflected as very high impedance.¹

Question 5

What are the common DBS brain targets (STN, GPi, VIM), and how does target choice affect system goals?

Accepted Answer

This question connects your anatomy to the goals develped by your discussion with your medical team, and it's one of the most important “systems” concepts in DBS.³ A DBS system can only deliver stimulation where the lead contacts sit, so choosing a target sets the boundaries for what symptoms are most likely to improve and what side effects are more likely when stimulation spreads.³

Target choice is not a statement that one target is “better” in general, it is a structured tradeoff based on diagnosis, symptom priorities, medication response patterns, and patient-specific risk factors.³ It also has workflow implications, because different targets can differ in typical programming approach and medication adjustment patterns, even though these differences are not absolute.³

For example, in Parkinson’s disease the subthalamic nucleus (STN) and globus pallidus internus (GPi) are widely used targets, and ventral intermediate nucleus (VIM) of the thalamus is commonly used for tremor-dominant indications.³ For essential tremor, VIM is a standard target because tremor circuits pass through thalamic pathways that VIM stimulation can modulate.⁵ For dystonia, GPi is commonly targeted, and STN is also used in some cases, with evidence suggesting both can improve dystonia outcomes, though patient selection and etiology matter.⁶

Target choice affects system goals because different targets sit in different circuit positions and are near different neighboring pathways.³ That proximity influences both benefit and side effects, for example, stimulation near internal capsule fibers can cause muscle pulling or speech changes at higher amplitudes, and clinicians try to balance symptom improvement against such spread-related effects.¹,³

The use of STN and GPi for Parkinson’s disease and VIM for tremor is well established in clinical literature.³,⁵ Dystonia target outcomes show benefit across GPi and STN in systematic reviews, but the best target for a specific dystonia subtype can remain uncertain and should be framed as a clinician-level decision with shared goals.⁶

Glossary:

Subthalamic nucleus (STN): A basal ganglia target commonly used in Parkinson’s disease DBS, often chosen when medication reduction and motor fluctuation control are key goals.³

Globus pallidus internus (GPi): A basal ganglia output target used in Parkinson’s disease and dystonia, often discussed in relation to dyskinesia control and broader motor modulation.³,⁶

Ventral intermediate nucleus (VIM): A thalamic target strongly associated with tremor suppression, particularly in essential tremor and tremor-dominant presentations.³,⁵

Stimulation spread: Unintended activation of nearby neural pathways when the electric field extends beyond the desired region.¹,³

Question 6

How does laterality work, left brain vs right brain, and why does that matter for symptoms?

Accepted Answer

Many DBS conversations use “left” and “right” in ways that can be confusing, left brain target, right body symptoms, and sometimes left-sided tremor versus right-sided tremor.⁷ The nervous system is organized so that many motor pathways cross, meaning one hemisphere often has a stronger influence on movement on the opposite side of the body.⁷ This becomes clinically relevant because DBS is typically programmed separately for each side, and clinicians often prioritize the side with the most disabling symptoms.¹
A common simplification used in clinic is that left hemisphere stimulation is often more directly related to right-sided limb motor control, and right hemisphere stimulation is often more directly related to left-sided limb motor control, because of corticospinal tract decussation.⁷ This is not the full story because axial symptoms and some functions have more bilateral control, and because basal ganglia circuits are not identical to corticospinal tracts, but the contralateral pattern is still a useful anchor for understanding programming discussions.⁷ When someone says “your right hand tremor improved when we increased the left side,” that statement is consistent with the way major motor pathways are organized.⁷

Laterality also matters for side effects, because speech, mood, and cognitive effects can be influenced by which circuits are stimulated and by hemispheric specialization, and clinicians may be more conservative when adjusting one side if side effects appear.³ This is one reason detailed symptom tracking by body side and by timing can help clinic teams map benefit and side effects to specific settings.¹

Contralateral limb motor control via the lateral corticospinal tract and pyramidal decussation is well established neuroanatomy and is clearly described in authoritative clinical references.⁷ The degree to which DBS effects follow a simple contralateral rule varies by symptom type and circuit involvement, so clinicians often confirm laterality effects empirically during programming rather than assuming them.¹,³

Glossary:

Laterality: The concept of left versus right sided brain stimulation and left versus right sided symptoms, used to organize programming and clinical interpretation.¹

Contralateral: Opposite-sided, such as left brain pathways influencing right limb movement.⁷

Axial symptoms: Symptoms affecting midline functions like posture, gait, and trunk control, which often involve more bilateral control.⁷

Hemispheric specialization: Differences in function between left and right hemispheres that can influence non-motor effects depending on stimulation location.³

Question 7

What is meant by “unilateral” vs “bilateral” DBS, and how does hardware differ?

Accepted Answer

Unilateral and bilateral is not just some clinical choice, it's also hardware configurations with practical implications for surgery, battery use, and future expansion.¹ Unilateral DBS means stimulation is delivered to one hemisphere, usually through one implanted lead, while bilateral DBS means stimulation is delivered to both hemispheres, usually through two leads.¹ The hardware matters because some IPGs are designed with a single set of ports for one lead, and others include ports for two leads, which affects whether one IPG can run both sides.¹

Unilateral systems often involve one lead, one extension, and either a unilateral-capable IPG or a bilateral-capable IPG used with one side connected.¹ Bilateral stimulation can be delivered using one dual-channel IPG connected to two leads, or using two separate IPGs, one for each side, depending on the system model and clinical plan.¹ Some MRI-conditional labeling and implant-routing requirements become more specific when two stimulators are used, because component placement and side-matching can affect MRI conditions of use.⁸

Clinically, unilateral DBS is sometimes considered when symptoms are strongly one-sided or when clinicians want to limit risk and complexity, while bilateral DBS is more common when disabling symptoms affect both sides.³ The right choice is diagnosis and goal dependent, and it is typically decided through a shared decision process that considers expected benefit, risks, and lifestyle factors such as recharge capacity and follow-up access.³

The relationship between unilateral versus bilateral stimulation and header port design is described in technical DBS system reviews.¹ MRI-related constraints for multi-component systems are specified in manufacturer MRI guidelines and can differ by configuration.⁸ The clinical decision between unilateral and bilateral implantation depends on individual circumstances and has no single universally correct approach.³

Glossary:

Unilateral DBS: DBS delivered to one brain hemisphere, typically with one implanted lead.¹

Bilateral DBS: DBS delivered to both hemispheres, typically with two implanted leads.¹

Dual-channel IPG: An IPG designed to support stimulation for two leads, usually through two header ports.¹

MR Conditional: A labeling category meaning MRI can be performed only under specific conditions defined by the manufacturer.⁸

Question 8

What DBS manufacturers and system “families” exist today, and what are the major differences between them?

Accepted Answer

DBS is a therapy category, not a single product, and major device manufactureres differ in power strategy, programming features, lead designs, and MRI labeling details.¹,² In many countries, DBS systems are supplied by a small number of large manufacturers, and local availability can be shaped by hospital contracts and national authorization pathways.¹,⁹ When people compare devices, it is easy to get pulled into brand claims, so it helps to focus on architecture-level differences like current control, recharge strategy, sensing, and software ecosystem.¹,¹⁰
In the United States, DBS systems are marketed primarily by Medtronic, Abbott, and Boston Scientific, and these same companies supply many other regions as well, though exact model availability depends on regional regulatory status and procurement.⁹,¹⁰

In the European Union, manufacturers place devices on the market after conformity assessment and CE marking under the EU medical device framework, which is a different regulatory pathway than U.S. FDA approval and does not use identical labeling language.¹¹ In the United Kingdom, the MHRA oversees medical device regulation, and CE marking is currently recognized in Great Britain under defined timelines while the UKCA framework applies for Great Britain market access.¹² In Canada, devices generally require licensing and appear in Health Canada’s medical device licence listings for the classes that require licenses.¹³ In Japan, higher-risk medical devices requiring approval involve PMDA review for safety and efficacy as part of the MHLW approval pathway.¹⁴
Common “design philosophy” differences that show up in daily life include how the device controls output, how it supports field shaping, and how it handles long-term power.¹,¹⁰ These are not value judgments, they are engineering choices that create different strengths and constraints for different patients and clinics.¹
The presence of three dominant commercial DBS manufacturers is documented in technical reviews and in U.S.-focused patient education resources, and manufacturer labeling provides the definitive feature sets for specific models.¹,⁹ Regulatory pathway descriptions are well established on official regulator sites, but the practical availability of a given model can change over time and varies by country and institution.¹¹–¹⁴

Glossary:

Device family: A related set of DBS products from one manufacturer designed to work together across leads, extensions, IPGs, and software.¹

Regulatory pathway: The formal process a region uses to authorize medical devices for marketing, such as FDA approval in the U.S. or CE marking in the EU.¹¹

CE mark: A marking indicating a device has passed conformity assessment requirements to be placed on the EU market.¹¹

UKCA mark: A UK product marking indicating conformity with Great Britain medical device requirements.¹²

Device licensing: A national authorization process, such as Health Canada medical device licensing for eligible device classes.¹³

Question 9

What is the difference between a platform, a model, and a software generation in DBS systems?

Accepted Answer

People often hear multiple names for what seems like “the device,” and those names may refer to different layers.¹

A model is usually a specific hardware product with defined physical characteristics and labeling, such as a particular IPG type or lead.¹,¹⁰

A platform often refers to a broader system ecosystem, hardware plus programmer software plus compatible leads and extensions, that supports a consistent workflow and feature set across multiple models.¹,¹⁰

Software generation refers to the programmer and device firmware capabilities that can change how settings are displayed, how data is logged, or how programming features work, even when the implanted hardware is similar.¹,¹⁰
These distinctions are important because compatibility is not automatic across layers.¹ Leads and extensions are generally designed to match a manufacturer’s system family, and mixing components across manufacturers usually requires specific adapters and is not always an option.¹ Regulatory labeling also tends to attach to specific models and configurations, which is especially important for MRI conditionality and for indication-specific claims.²,⁸
A practical way to use these terms is to ask, 
“Are we talking about implanted hardware, external programmer software, or both.”¹ 
That question often clarifies confusion when a clinic mentions an “upgrade” that might mean a new IPG model at replacement, a new programming software release, or a new therapy feature that requires both.¹,¹⁰

The concept of system families, component compatibility, and the role of software features is described in technical DBS system reviews and is reflected in manufacturer product documentation.¹,¹⁰ The exact naming conventions for “platform” and “generation” are not standardized across manufacturers, so the safest approach is to confirm the exact model numbers and software versions used by the treating clinic.¹,¹⁰

Glossary:

Model: A specific DBS hardware product with defined specifications and labeling, such as a particular IPG or lead.¹

Platform: A broader ecosystem of compatible implanted components and external programming tools that share a common design framework.¹

Firmware: Internal software on the implanted device that controls behavior, safety checks, and communication features.¹,¹⁰

Compatibility: The ability of leads, extensions, IPGs, and software tools to function together as intended within labeled configurations.¹

Question 10

What questions help me compare DBS  systems without getting lost in "marketing language"?

Accepted Answer

DBS decisions can feel high-stakes, and high-stakes decisions attract simplified claims.¹,⁹

A useful comparison approach is to translate “features” into measurable daily-life consequences, clinic workflow implications, and safety labeling constraints.¹,² The goal is not to become a device expert, it is to make sure the conversation stays anchored to your priorities, your access to follow-up care, and your medical constraints like MRI needs.⁸,¹⁰

Questions work best when talking with your medical team as they point to documents and workflows rather than opinions.² They also work best when they are framed as shared problem-solving with your clinician, because device choice is often constrained by what a center supports and what is authorized in your region.¹,¹¹–¹⁴
The question below are designed to even out differences in a consistent way.¹,² Each one can be answered with a combination of clinician experience and manufacturer labeling, and that combination tends to be more reliable than general advertising language.²,⁸,¹⁰
 • “Which specific model numbers are you recommending, and what features in the labeling match my goals.” This forces the discussion to stay tied to identifiable products rather than broad brand categories.² It also matters because MRI conditionality, recharge requirements, and sensing features can vary within the same manufacturer across models.⁸,¹⁰
 • “How will this system affect my MRI options over the next decade, including body region limits and required conditions.” This question is practical because MRI conditional labeling is configuration-specific, and a person’s need for MRI can change as other health issues arise.⁸ It also invites the clinic to explain the “conditions of use,” which are the real constraints, rather than using the vague phrase “MRI safe.”⁸
 • “What is the expected follow-up schedule for programming and battery management with this device, and what happens if I move or travel.” This matters because DBS benefit often depends on iterative programming, and access to a trained team is part of the therapy system even though it is not implanted hardware.³ It also connects directly to recharge routines, remote support policies, and long-term maintenance planning.¹,¹⁰
 • “Does this system support sensing or data logging, and if so, how does your clinic use it in real decision-making.” This clarifies whether sensing is a meaningful clinical tool at your center or mainly a feature that is not routinely used.¹⁰ It also helps you understand what “data” is collected, how it is interpreted, and what uncertainties remain about linking signals to symptoms.¹⁰
Comparing DBS devices through labeling-driven questions is strongly supported by how DBS systems are regulated, documented, and managed in clinic, and manufacturer MRI guidelines are the authoritative source for MRI constraints.²,⁸ The clinical value of some advanced features, particularly sensing-guided programming, is evolving and can vary widely by center expertise and by patient situation.¹⁰

Glossary:

Labeling: The official device documentation describing intended use, indications, warnings, and conditions, often tied to regulatory authorization.²

MR Conditional conditions of use: The specific scanning rules that must be followed for MRI to be permitted with an implanted system.⁸

Sensing: Device capability to record bioelectric signals, which may support clinician interpretation and research, depending on system and workflow.¹⁰

Programming workflow: The clinic process of iterative setting adjustments based on symptom response and side effect thresholds.³

Question 11

Which system features matter most for long-term living, sensing, recharge routines, MRI access, size, and longevity?

Accepted Answer

DBS is a long-term therapy, and long-term satisfaction often depends on “maintenance features” rather than only initial symptom response.¹,³

Features like recharge burden, MRI labeling, and device longevity affect daily routines and healthcare access for years, which can shape quality of life.⁸,¹⁰ Many features also interact, for example, higher energy settings can shorten battery life, and sensing or data features may influence power consumption depending on design.¹

The most durable approach is to think in categories that map to real-life tasks, travel, clinic visits, and future health needs.¹,³ This also helps you avoid overfocusing on any single specification, because tradeoffs are normal and not always obvious from brochures.¹,¹⁰
 • Rechargeable versus non-rechargeable IPGs: Rechargeable systems can reduce the frequency of surgical replacements, but they require regular charging routines and reliable access to chargers and follow-up support.¹ The practical “fit” depends on comfort with routine charging, skin sensitivity at the implant site, and the stability of life circumstances that support consistent device care.¹,¹⁰
 • MRI conditionality and MRI workflow: MRI access is not a single yes or no, it is a set of conditions tied to the exact implanted configuration and scanning parameters, and those conditions can differ between manufacturers and models.⁸ Clinics may require device checks before and after scans, and some systems have additional constraints when two IPGs are implanted or when mixed-component configurations are used.⁸
 • Sensing and data features: Some systems advertise the ability to record or use brain signals, and the real question is how your clinical team uses those capabilities for decisions rather than whether the feature exists.¹⁰ Manufacturer documentation can confirm the presence of sensing features on specific models, but day-to-day value depends on trained interpretation and clear clinical goals.¹⁰
 • Size, pocket comfort, and surgical replacement planning: IPG size and shape can influence comfort, especially for people with low body fat over the implant area, and replacement planning matters because every replacement is a procedure with its own risks.¹,³ While manufacturers describe device form factors, your surgeon and clinic can translate that into expected pocket placement and comfort considerations for your body.¹

Rechargeable versus non-rechargeable tradeoffs and the role of MRI conditional labeling are well established in DBS technical reviews and manufacturer MRI guidelines.¹,⁸ The long-term clinical impact of sensing features is still developing, and benefits may be strongest in centers that have integrated sensing into structured programming and research workflows.¹⁰

Glossary:

Rechargeable IPG: An IPG with a battery designed to be recharged through the skin using an external charger at intervals defined by usage and device design.¹

Non-rechargeable IPG: An IPG with a primary battery that is replaced surgically when depleted.¹

Longevity: The expected time until battery depletion or replacement need, influenced by stimulation settings and device design.¹

Pocket: The subcutaneous space where the IPG is implanted, commonly in the chest region.¹

Data logging: Storage of device-related measurements or events that can be reviewed during clinical follow-up, depending on system capabilities.¹⁰

Question 12

What are the external tools, and what do they actually do beyond “turning it up or down”?

Accepted Answer

There are two primary external tools are the interface between real-world life and the implanted circuit.¹,¹³,¹⁴
1. Clinician-side tools: Clinician software can set stimulation parameters, define patient adjustment limits, run diagnostics like impedance checks, and manage device modes used during certain procedures.¹,⁸,¹⁴ These tools also increasingly serve as the gateway for features like sensing, data review, and adaptive algorithms when available and enabled.¹,²,¹⁴
2. Patient-side tools: Patient programmers typically allow limited adjustments within clinician-defined boundaries, and they may also show device status and support special modes, depending on system and labeling.¹⁴ Importantly, patient tools are part of the therapy safety design, because limiting what can be changed reduces the risk of inadvertently entering unsafe or destabilizing parameter ranges.⁸,¹⁴

Question 13

What DBS manufacturers and system “families” exist today, and what are the major differences in design philosophy?

Accepted Answer

Historically, major global manufacturers have included Medtronic, Abbott (formerly St. Jude Medical), and Boston Scientific; more recent entrants in some regions include PINS Medical, SceneRay, and Newronika.¹

Design philosophies that tend to differ (even when everyone claims “precision”). Systems vary in contact architecture (ring vs segmented, contact count), stimulation control strategy (constant-current vs constant-voltage, and how current is distributed across contacts), and how deeply sensing and adaptive features are integrated.¹,²,⁵,¹⁴ These differences shape the practical experience of programming, follow-up workflows, and the long-term “complexity load” for patients and clinics.¹,²

A crucial reality check. The most meaningful differences are often in what is enabled and labeled for your region and your exact model, not just what is technically possible in a lab, so comparing “families” should always end with a model-specific labeling review.¹,⁸,¹³,¹⁴

Question 14

Which system features tend to matter most for long-term living: sensing, recharge routines, MRI access, size, and longevity?

Accepted Answer

Long-term living is where the technology stops being abstract and starts feeling like a daily companion, sometimes helpful, sometimes heavy. These features commonly shape that experience.⁶
 • Rechargeability and charging ecosystem. Rechargeable IPGs can reduce the frequency of surgical replacements for battery depletion, but they add routine charging behaviors and require sustained adherence, which can be a strength or a burden depending on the person.⁶,¹⁴ Non-rechargeable systems remove that routine but may require more frequent replacement surgeries depending on energy use.⁶,⁸
 • Battery longevity and energy drivers. Longevity depends on stimulation amplitude, pulse width, frequency, number of active contacts, and measured impedance, plus how often the device communicates with external controllers.⁶,⁸ In other words, “battery life” is not just a spec sheet number, it is a function of your programmed therapy and your device interactions over time.⁶,⁸
 • Sensing and adaptive features. Some platforms can record physiological signals (for example, local field potentials) and can use them to adjust stimulation amplitude within clinician-defined limits when adaptive DBS is enabled and labeled.¹⁴ This can change follow-up strategy and data discussions, but it also introduces new constraints and new failure modes, such as signal-quality dependence and electromagnetic compatibility considerations.¹⁴
 • MRI access and other procedure interactions. MRI labeling is system-specific and model-specific, and it can change over time through regulatory supplements; some systems, at least in certain labeling versions, have been described as MR unsafe, while others may be MR conditional under strict conditions.⁸,¹³ Because MRI conditions are high-stakes, the only safe approach is to verify your exact implanted components against the manufacturer’s MRI guidelines and your clinic’s workflow each time an MRI is considered.⁸

Question 15

Sources

Accepted Answer

1. Amon A, Alesch F. Systems for deep brain stimulation: review of technical features. J Neural Transm (Vienna). 2017;124(9):1083-1091. doi:10.1007/s00702-017-1751-6. PMID: 28707160. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC5565669/
(https://pmc.ncbi.nlm.nih.gov/articles/PMC5565669/?utm_source=chatgpt.com)
2. US Food and Drug Administration. Vercise™ Deep Brain Stimulation (DBS) System, P150031C, Summary of Safety and Effectiveness Data (SSED). FDA. Published 2017. Available at: https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150031C.pdf
(https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150031C.pdf?utm_source=chatgpt.com)
3. Fukaya C, Yamamoto T. Deep brain stimulation for Parkinson’s disease: recent trends and future direction. Neurol Med Chir (Tokyo). 2015;55(5):422-431. doi:10.2176/nmc.ra.2014-0446. PMID: 25925761. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4628170/
(https://pmc.ncbi.nlm.nih.gov/articles/PMC4628170/?utm_source=chatgpt.com)
4. Medtronic. SenSight™ directional lead. Medtronic website. Available at: https://www.medtronic.com/en-us/healthcare-professionals/products/neurological/deep-brain-stimulation/dbs-therapy-leads/sensight-directional-lead.html
(https://www.medtronic.com/en-us/healthcare-professionals/products/neurological/deep-brain-stimulation/dbs-therapy-leads/sensight-directional-lead.html?utm_source=chatgpt.com)
5. Patel A, Okun MS. Deep brain stimulation management of essential tremor with dystonic features. Tremor Other Hyperkinet Mov (N Y). 2018;8:426. doi:10.5334/tohm.426. Available at: https://tremorjournal.org/articles/10.5334/tohm.426
(https://tremorjournal.org/articles/10.5334/tohm.426?utm_source=chatgpt.com)
6. Fan H, Zheng Z, Yin Z, et al. Deep brain stimulation treating dystonia: a systematic review of targets, body distributions and etiology classifications. Front Hum Neurosci. 2021;15:757579. doi:10.3389/fnhum.2021.757579. Available at: https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2021.757579/full
(https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2021.757579/full?utm_source=chatgpt.com)
7. Javed K, Reddy V, Lui F. Neuroanatomy, lateral corticospinal tract. In: StatPearls. StatPearls Publishing; updated 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK534818/
(https://www.ncbi.nlm.nih.gov/books/NBK534818/?utm_source=chatgpt.com)
8. Boston Scientific. ImageReady™ MRI Guidelines for Boston Scientific Deep Brain Stimulation Systems. Boston Scientific eLabeling (PDF). Available at: https://www.dbsandme.com/content/dam/elabeling/nm/92438760-07_Rev_A_IR_MRI_GuidelinesforBS_DBS_Sys_IFU_MRI_EN_s.pdf
(https://www.dbsandme.com/content/dam/elabeling/nm/92438760-07_Rev_A_IR_MRI_GuidelinesforBS_DBS_Sys_IFU_MRI_EN_s.pdf?utm_source=chatgpt.com)
9. The Michael J. Fox Foundation for Parkinson’s Research. Choosing a deep brain stimulation device. MJFF website. Available at: https://www.michaeljfox.org/news/choosing-deep-brain-stimulation-device
(https://www.michaeljfox.org/news/choosing-deep-brain-stimulation-device?utm_source=chatgpt.com)
10. Medtronic. Percept™ PC neurostimulator with BrainSense™ technology. Medtronic website. Available at: https://www.medtronic.com/en-us/healthcare-professionals/products/neurological/deep-brain-stimulation/electrical-stimulation-systems/percept-pc-neurostimulator.html
(https://www.medtronic.com/en-us/healthcare-professionals/products/neurological/deep-brain-stimulation/electrical-stimulation-systems/percept-pc-neurostimulator.html?utm_source=chatgpt.com)
11. European Medicines Agency. Medical devices. EMA website. Updated December 10, 2025. Available at: https://www.ema.europa.eu/en/human-regulatory-overview/medical-devices
(https://www.ema.europa.eu/en/human-regulatory-overview/medical-devices?utm_source=chatgpt.com)
12. Medicines and Healthcare products Regulatory Agency (MHRA). Regulating medical devices in the UK. GOV.UK. Available at: https://www.gov.uk/guidance/regulating-medical-devices-in-the-uk
(https://www.gov.uk/guidance/regulating-medical-devices-in-the-uk?utm_source=chatgpt.com)
13. Health Canada. Medical Devices Active Licence Listing (MDALL). Government of Canada website. Updated July 26, 2024. Available at: https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/licences/medical-devices-active-licence-listing.html
(https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/licences/medical-devices-active-licence-listing.html?utm_source=chatgpt.com)
14. Pharmaceuticals and Medical Devices Agency (PMDA). Regulations and Approval/Certification of Medical Devices. PMDA website. Available at: https://www.pmda.go.jp/english/review-services/reviews/0004.html.(https://www.pmda.go.jp/english/review-services/reviews/0004.html?utm_source=chatgpt.com) Accessed January 10, 2026.

DEEP BRAIN STIMULATION

DBS DEEP DIVE

BACK TO DBS HUB | BACK TO DBS DEEP DIVE

Complete DBS System Overview

BACK TO DBS HUB | BACK TO DBS DEEP DIVE

DBS Systems and Hardware

More Information Coming Soon!

DON'T TAKE OUR WORD FOR IT . . .

CONNECT WITH US

JOIN OUR MAILING LIST